YOLFTbeta
Immuneering Corp

Immuneering Corp

IMRX · NASDAQ · Healthcare / Biotechnology

3.71USD+0.04 (+1.09%)

Price History

Full chart

Market Stats

Previous Close3.67
Open3.71
Day Range3.55 – 3.75
52-Week Range3.86 – 8.48
Volume847.34K
Market Cap276.26M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.93
Dividend Yield0.00%
Beta0.39
50-Day Avg4.67
200-Day Avg5.09

About

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Benjamin J. Zeskind M.B.A., Ph.D.
  • Employees57
  • Headquarters245 Main Street, Cambridge, MA, United States, 02142, USA
  • Websitehttps://immuneering.com

Leadership

  • Dr. Benjamin J. Zeskind M.B.A., Ph.D.Co-Founder, President, CEO & Director · b. 1983
  • Mr. Robert J. Carpenter M.B.A., M.S.Co-Founder & Chair Emeritus · b. 1946
  • Dr. Brett M. Hall Ph.D.Chief Scientific Officer · b. 1969
  • Mr. Michael D. Bookman J.D.Chief Legal Officer & Secretary · b. 1987
  • Mr. Andrew W. GengosCFO & Treasurer · b. 1964
  • Ms. Paula George CPASenior Director of Accounting & Operations and Assistant Corporate Controller
  • Ms. Mallory Morales CPASenior VP of Finance, Chief Accounting Officer & Assistant Treasurer · b. 1983
  • Ms. Jyoti JoshiDirector of Quality Systems & Compliance
  • Mr. David CaouetteVice President of Corporate Communications
  • Ms. Leah R. NeufeldChief People Officer · b. 1972

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.92M2.31M2.08M316.95K45500
Growth (%)-+20.41%-10.02%-84.76%-99.86%-100.00%-
Cost of Revenue1.22M1.28M1.15M158.12K764.14K713.45K698.89K
Gross Profit696.74K1.03M926.89K158.83K-764.14K-713.45K-698.89K
Gross Margin36.29%44.61%44.56%50.11%-167942.42%--
Operating Expense6.99M18.11M34.81M51.90M57.65M63.36M58.68M
Operating Income-6.29M-17.08M-33.89M-51.74M-58.41M-64.07M-59.38M
Operating Margin-327.71%-739.01%-1629.17%-16325.77%-12837997.14%--
EBITDA-7.34M-17.00M-33.73M-51.47M-58.06M-63.69M-55.33M
EBITDA Margin-382.35%-735.58%-1621.52%-16238.45%-12760703.74%--
Net Income-7.71M-17.04M-33.54M-50.51M-53.47M-61.04M-56.02M
Net Income Margin-401.59%-737.17%-1612.33%-15937.29%-11752004.84%--
R&D4.28M15.00M26.54M36.27M41.62M47.96M42.05M
R&D as % of Total Revenue222.89%649.08%1276.03%11442.46%9148135.82%--
Interest Expense351.30K42.66K201.91K1.01M---
Interest Expense % of Total Revenue18.30%1.85%9.71%320.07%---

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets14.10M38.42M166.70M122.37M102.58M52.71M231.99M
Total Liabilities20.63M60.90M10.72M12.52M12.01M11.33M13.50M
Total Equity-6.53M-22.48M155.98M109.85M90.58M41.39M218.48M
Cash13.78M37.09M74.89M72.64M59.41M36.14M128.65M
Total Debt16.61M621.09K5.36M4.84M4.46M4.16M3.82M
Net Debt-13.78M-36.47M-69.52M-67.80M-54.94M-31.98M-124.82M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.44M-14.62M-30.85M-44.10M-48.97M-55.00M-45.34M
Investing Cash Flow-20.53K-53.41K-75.62M41.83M7.30M26.43M-88.74M
Financing Cash Flow17.17M37.98M144.26M19.00K28.44M5.30M226.58M
Capital Expenditure20.53K53.41K60.79K742.49K342.75K84.88K142.23K
Free Cash Flow-4.46M-14.67M-30.91M-44.84M-49.31M-55.08M-45.49M
FCF to OCF100.46%100.37%100.20%101.68%100.70%100.15%100.31%

Earnings

Report DateMar 31, 2020Mar 31, 2021Jun 2, 2021Sep 9, 2021Nov 9, 2021Mar 10, 2022May 10, 2022Aug 10, 2022Nov 10, 2022Mar 6, 2023May 4, 2023Aug 3, 2023Nov 9, 2023Mar 1, 2024May 7, 2024Aug 6, 2024Nov 13, 2024Mar 20, 2025May 5, 2025Aug 13, 2025Nov 12, 2025Mar 6, 2026May 12, 2026Aug 5, 2026Nov 11, 2026
EPS Estimate0.000.00-1.25-1.44-0.62-0.39-0.44-0.52-0.48-0.58-0.56-0.53-0.49-0.47-0.50-0.53-0.55-0.45-0.58-0.40-0.39-0.31-0.35-0.26-0.29
EPS Actual-0.65-1.26-1.26-1.61-0.47-0.42-0.49-0.44-0.49-0.50-0.51-0.43-0.43-0.52-0.49-0.47-0.49-1.07-0.42-0.40-0.38-0.18-0.21-0.27-
Surprise---0.80%-11.81%24.19%-7.69%-11.36%15.38%-2.08%13.79%8.93%18.87%12.24%-10.64%2.00%11.32%10.91%-137.78%27.59%0.00%2.56%41.94%40.00%-3.85%-
Timing---Pre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursPre-market-Pre-marketPre-market

Key Statistics & Ratios

Market Cap276.26M
Enterprise Value137.75M
Trailing P/E0.00
Forward P/E0.00
Price / Sales563.62
Price / Book1.49
EPS-0.93
Book Value2.95
Revenue (TTM)455
Gross Profit (TTM)158.83K
EBITDA-63.12M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-52.15%
Return on Assets-32.77%
Shares Outstanding64.70M
Shares Float49.21M
Beta0.39
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 17.17
  • Strong Buy
    2
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
55.44%
Insiders
13.82%
Retail / Other
30.74%

Top Institutional Holders

  • FMR Inc
    9.70M14.99%
  • Sanofi
    2.71M4.19%
  • Vanguard Capital Management, LLC
    2.29M3.54%
  • Marshall Wace Asset Management Ltd
    2.00M3.09%
  • T. Rowe Price Associates, Inc.
    1.83M2.83%
  • BlackRock Inc
    1.51M2.33%
  • DCF Advisers, LLC
    790.00K1.22%
  • Geode Capital Management, LLC
    637.94K0.99%
  • Occam Crest Management L.P.
    545.10K0.84%
  • Summit Financial LLC
    452.26K0.70%
  • Easterly Investment Partners.
    414.00K0.64%

Top Fund Holders

  • HBM Healthcare Investments AG Ord
    3.65M5.64%
  • Fidelity Growth Company Fund
    2.94M4.54%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.62M2.51%
  • iShares Russell 2000 ETF
    1.34M2.08%
  • Fidelity Select Biotechnology
    1.10M1.69%
  • Fidelity Growth Company K6
    831.69K1.29%
  • Fidelity Series Growth Company
    719.80K1.11%
  • Fidelity Small Cap Index
    582.85K0.90%
  • iShares Russell 2000 Value ETF
    491.35K0.76%